The Market Access Special Forces

As partners of our internationally operating clients, we support the successful market access especially of treatments for rare diseases, of ATMPs or of products which set new therapy standards, both on a strategic and operational level.
The EU HTA scoping process: a puzzle to be solved

SKC simulation of the expected PICO schemes on EU Big 6
Market access for gene therapies

Our exclusive white paper provides a comprehensive analysis to derive key considerations for the strategic challenges for gene therapies in Germany, with a focus on pricing and reimbursement
Whitepaper: Routine practice data collection for benefit assessment

Lessons learned from 2 years - risk factors and strategic implications
Digital Health Applications (DiGAs)

With our longstanding AMNOG-expertise we support DiGA-providers with a customized market access strategy – all the way from the development of the value story to successful price negotiations.
Creating value in health care

"A unique combination of deep understanding of the matter, strategic vision, didactic skill and humor."

Founder and CEO of medical-technology company

What drives usOur insights

2nd to 4th of Oct 2023
Prof. Matthias P. Schönermark, M.D., Ph.D.

Excellence for Market & Patient Access, Pricing and Reimbursement

to the top